You are here

Article Text

Article menu
Download PDFPDF
Short report
Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy
  1. Gurdesh Bedi,
  2. Andrew Brown,
  3. Tao Tong,
  4. Khema R Sharma
  1. Department of Neurology, University of Miami, Miller School of Medicine, Miami, Florida, USA
  1. Correspondence to Dr K R Sharma, Department of Neurology, University of Miami, Miller School of Medicine (M740), 1150 NW 14th Street, Room # 609, Miami, FL 33136, USA; ksharma{at}med.miami.edu

Abstract

Objective To evaluate the efficacy of mycophenolate mofetil (MMF) in chronic inflammatory demyelinating polyneuropathy (CIDP).

Background Evidence is growing that MMF is effective as an immunomodulatory drug in neuromuscular diseases.

Methods A database of 184 patients with CIDP was analysed to obtain clinical, laboratory and electrophysiological information for patients with CIDP treated with MMF.

Results Eight patients, who met the inclusion criteria, received MMF (mean dose 2 g/day; median duration 15.2 months). The average Neuropathy Impairment Score of the eight patients improved from baseline (72.3±35) after initiation of MMF therapy (37.8±37; p<0.001). Six of these eight patients were either able to stop concomitant medications (corticosteroid, intravenous immunoglobulin) or reduce their doses and frequency by ≥50%.

Conclusions Our pilot data suggest that MMF appears to be an effective therapy for patients with naive or refractory CIDP, and further controlled studies are warranted for their confirmation.

https://doi.org/10.1136/jnnp.2009.177576

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Presented as an abstract at the 61st AAN meeting, 25 April to 2 May, 2009, Seattle, Washington, USA.

    • Competing interests None.

    • Ethics approval This study was conducted with the approval of the Institutional Review Board, University of Miami Miller School of Medicine, Miami, Florida, USA.

    • Provenance and peer review Not commissioned; externally peer reviewed.